Placenta Previa and Placenta Percreta Patients During the Third Trimester

May 16, 2026 updated by: Celal Bayar University

Investigation of the Expression of Glycoproteins, Collagen, and Growth Factors in Patients With Placenta Previa and Placenta Percreta During the Third Trimester of Pregnancy

Placenta previa can cause a risk of severe bleeding during labor. Placenta previa is usually classified into four different types: total, partial, marginal and asymptomatic. The condition is diagnosed by ultrasonography later in pregnancy and its management varies depending on the location of the placenta and the presence of bleeding. Studies show that the increased frequency of placenta previa is associated with increased cesarean section rates and maternal age (1). Furthermore, the effects of placenta previa on maternal and fetal morbidity can be reduced with proper management (2).

Placenta percreata is a condition in which the placenta invades the myometrium (uterine muscle) and serosa (outer surface of the uterus). This can make postpartum detachment of the placenta difficult, leading to severe bleeding and complications. Placenta perforata is often associated with placenta previa and may require surgical intervention. Ultrasonography and magnetic resonance imaging (MRI) are used to diagnose this condition. Risk factors include previous cesarean deliveries and placenta previa (3). Placenta percreata requires careful management as it increases the risk of maternal mortality and morbidity (4).

In this study, we aimed to investigate the levels of decorin, laminin, collagen-1, TGFβ-1, PDGF in placentas of pregnant women with placenta percreata and previa.

Study Overview

Status

Completed

Conditions

Detailed Description

In the hospital, blood tests are routinely taken preoperatively from patients hospitalized for placenta percreata and preavia. Blood samples of patients who do not have exclusion criteria and who agree to participate in the study will also be studied from routinely collected blood samples. During the hospitalization of these patients for delivery, following the clamping of the umbilical cord after the birth of the baby (after the bond between the mother and the baby is terminated), 2 ml (one teaspoon) of blood sample will be taken from the cord blood, centrifuged and the serum sample will be separated and stored at -80 degrees. A 3x3 cm piece will be taken from the umbilical cord and placenta (the baby's mate), which will be disposed of as medical waste in the postnatal process, covering all layers. The tissue samples will be placed in a container with 10% formol and preserved. At the time of umbilical cord blood and placenta sampling, these tissues are in a waste state and have no connection with the baby and mother, so there is no harm to the mother or baby during sampling. Tissues (placenta, umbilical cord) and 2 ml (one teaspoon) of blood sample from umbilical cord blood will be taken, centrifuged and serum sample will be separated and stored at -80 degrees Celsius to be used in other similar studies and projects planned to be carried out in the future.

Patients to be selected for the control group will be determined according to the exclusion criteria and will be selected with a similar gestational week and gravida number as the case group (In other studies in the literature, control group patients were collected using this similarity). If the patients selected for the control group give birth at term, tissue samples will be taken. Umbilical cord blood will be collected and stored at -80 and included in the study.

If the patient selected for the control group gives birth prematurely, gives birth in an external center or requests to withdraw from the study, the patient will be excluded from the study.

Study Type

Observational

Enrollment (Actual)

48

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

women of Placenta percreata woman of Placenta previa

Description

Inclusion Criteria:

  • Healthy pregnancy under 37 weeks
  • Age range 18-50
  • Being literate in Turkish
  • Not having any additional disease
  • Agreeing to participate in the study

Exclusion Criteria:

  • High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.)

    • Multiple pregnancy
    • Pregnant women under the age of 18
    • Smoking
    • Medication use (excluding routinely used food supplements during pregnancy)
    • Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.)
    • Immunosuppressive use
    • Presence of active or chronic infection
    • Presence of active or chronic inflammatory disease
    • Patients who gave birth at an external center or later chose to withdraw from the study
    • Patients who did not have any exclusion criteria at the time of Placenta percrata/ placenta previa or when blood was drawn for the control group, but who later developed any exclusion criteria.
    • Premature birth of patients included in the control group

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group 1: Pregnant women with Placenta Percreata
Group 2: Pregnant women with Placenta Previa
Group 3: Control

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Percreta Tissues
Time Frame: Baseline
Placental tissue samples obtained at delivery from patients with placenta percreta will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.
Baseline
Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Percreta Pregnancies
Time Frame: Baseline
Maternal and cord blood samples collected from pregnancies complicated by placenta percreta will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.
Baseline
Mean Immunohistochemical Staining Score of Decorin, Laminin, Collagen-I, TGFβ-1, and PDGF in Placenta Previa Tissues
Time Frame: baseline
Placental tissue samples obtained at delivery from patients with placenta previa will undergo immunohistochemical staining for decorin, laminin, collagen-I, TGFβ-1, and PDGF. Staining intensity and distribution will be quantified using the H-score method.
baseline
Maternal and Cord Blood Concentrations of TGFβ-1 and Decorin in Placenta Previa Pregnancies
Time Frame: baseline
Maternal and cord blood samples collected from pregnancies complicated by placenta previa will be analyzed for TGFβ-1 and decorin concentrations using biochemical assay methods.
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Celal Bayar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2025

Primary Completion (Actual)

June 20, 2025

Study Completion (Actual)

November 20, 2025

Study Registration Dates

First Submitted

February 22, 2025

First Submitted That Met QC Criteria

February 22, 2025

First Posted (Actual)

February 27, 2025

Study Record Updates

Last Update Posted (Actual)

May 20, 2026

Last Update Submitted That Met QC Criteria

May 16, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MCBU- Perkreata-previa

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Placenta Previa

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe